Recent

% | $
Quotes you view appear here for quick access.

Avanir Pharmaceuticals, Inc. Message Board

  • greatdayforinvestments greatdayforinvestments May 3, 2013 3:18 PM Flag

    Fellow Longs "KEEP IN MIND" regarding Europe and the CHMP vote:

    On the regulatory front...
    12 months ago we had only just submitted our marketing authorization application to the European Medicines Agency...

    Today, we are a few short months away from an opinion on our application.

    These foundations firmly set us up for future success.

    FELLOW LONGS MOST IMPORTANTLY the CHMP " YES" vote opens the door to Avanir with following potential partnership's and R&D shared costs in Europe for:

    Agitation in Alzheimer's disease
    Central neuropathic pain in multiple sclerosis
    Levodopa induced dyskinesia in Parkinson's disease
    Autism
    Speech & Swallowing in ALS

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • "R&D shared costs in Europe for:

      Agitation in Alzheimer's disease
      Central neuropathic pain in multiple sclerosis
      Levodopa induced dyskinesia in Parkinson's disease
      Autism
      Speech & Swallowing in ALS"

      European partnership would just be the standard upfront license fee, royalties on European sales to Avanir and maybe milestone payments. Nothing to do with R&D. Even AVNR is not paying for the Levodopa induced dyskinesia in Parkinson's study, or speech and swallowing in ALS or autism.
      Avanir will continue to completely fund R&D for neuropathic pain and will hopefully cut bait sooner rather than later on agitation in dementia, but probably they'll waste more and more time and money on it because Avanir mistakenly thinks it makes for good advertising for the stock shares.